Last mentioned: Mar 16, 2026
Industry Warning
Editorials warn that erratic FDA behavior is a threat to biotech innovation.
Refusal to File
FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application.
Regulatory Alignment
FDA officials reportedly signal support for Moderna's trial data workaround.
Grant Rescission
The federal government rescinds hundreds of millions in mRNA research funding.
Peak Valuation
Moderna reaches a market capitalization of $200 billion during the pandemic height.
Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment.
This page surfaces every story mentioning Vinay Prasad across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Vinay Prasad was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |